
ImmuBYTES Session 3 Video Recording
DateCategory Watching Time 21 Minutes https://immuone.com/wp-content/uploads/2025/07/ImmuONE.mp4 Get in touch Add a Comment Related Posts
Following successful completion of the Phase 1 challenge awarded to ImmuONE by NC3Rs, we were announced as the winners for the Phase 2 challenge in January 2022. Sponsored by Unilever and AstraZeneca, the project aims to establish and develop in vitro OECD test guideline assays; free from animal-derived products and demonstrate their equivalence and superiority to current strategies. Once optimised, these technologies will progress to commercially ready, human relevant, animal-free bioassays with the view of gaining regulatory acceptance.
DateCategory Watching Time 21 Minutes https://immuone.com/wp-content/uploads/2025/07/ImmuONE.mp4 Get in touch Add a Comment Related Posts
In ImmuBYTES Session 3, “Looking Beyond Baseline Deviations for Lung and Immune Safety,” Prof. Victoria Hutter (CSO & Co-founder) highlighted how subtle changes in macrophage morphology can uncover early immune and lung effects.
Early detection of pulmonary ADC toxicity using ImmuONE’s morph_ONE™ high-content imaging assay of alveolar macrophages to improve safety and efficacy in ADC drug development.